Cardinal Health (CAH) Q1 FY2027 Earnings Call: Guidance and Outlook
The company raised its full-year fiscal 2027 EPS guidance and provided updated growth expectations for its Pharma and Other segments.
About Cardinal Health. Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets.
No specific quarterly guidance was given, though management noted earnings growth is expected to moderate in the second and third quarters before strengthening in the fourth.
Annual guidance
Non-GAAP diluted EPS
Raised to $12.80 to $13.
Pharma segment profit growth
Increased to 10% to 12%.
Other growth businesses revenue growth
Raised to 12% to 14%.
Other growth businesses profit growth
Raised to 17% to 20%.
Effective tax rate
Updated to 18.5% to 19.5%.
Adjusted free cash flow
Expected to be between $3.5 billion and $4 billion.
Outlook
Pharma demand
Expects strong demand to persist across core distribution, generic sourcing, and Specialty businesses.
Global Medical Products and Distribution
Sustained high petroleum costs are pushing segment profit toward the low end of the $200 million to $220 million range.
Other growth businesses
Anticipates revenue and profit growth to accelerate in the second half of the fiscal year.
Capital expenditure
Anticipated expenditure of approximately $700 million remains unchanged.
Regulatory environment
Management believes policy changes will be manageable and continues to engage with policymakers.
M&A strategy
Remains focused on integrating existing acquisitions and pursuing opportunities within the current three-legged stool strategy rather than seeking new areas.
Dombey's summary of the Cardinal Health Q1 FY2027 earnings call held Nov 5, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
